DNMT1 and acute myeloid leukemia: For example, in phase II/III of clinical trial NCT02472145, the use of a combination of the anti-CD123 (interleukin 3 receptor) monoclonal antibody talakotuzumab with the DNMT inhibitor decitabine was not more efficient than the treatment with decitabine alone in patients with acute myeloid leukemia (AML) [18].